Detail akcie Cellectar Bioscn Rg online

Business Summary: Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Cellectar Biosciences Inc revenues was not reported. Net loss increased 4% to $44.6M. Higher net loss reflects General and administrative increase from $9.8M to $24.9M (expense), Warrant issuance expense increase from $470K to $7.7M (expense), Research and development increase from $505K to $3.5M (expense).